An AACR Special Conference
Addressing Critical Questions in Ovarian Cancer Research and Treatment

October 1-4, 2017
Wyndham Grand Pittsburgh Downtown
Pittsburgh, Pennsylvania

CONFERENCE PROGRAM AND SCHEDULE

Sunday, October 1

Educational Session
Ballroom 1
4:00 p.m.-6:00 p.m.

Ovarian cancer: From prevention and early detection to biology, heterogeneity, and immunology
Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, Texas
Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, New York

Treatment of ovarian cancer: Present and future
Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, Massachusetts
Robert P. Edwards, University of Pittsburgh, Pittsburgh, Pennsylvania

Welcome Remarks and Opening Keynote Lecture
Ballroom 1
6:15 p.m.-7:30 p.m.

6:15 p.m.-6:30 p.m. Welcome Remarks
6:30 p.m.-7:15 p.m. Meeting the challenges in ovarian cancer
Joan S. Brugge, Harvard Medical School, Boston, MA

Opening Reception
King’s Garden 4-5
7:30 p.m.-9:30 p.m.

Monday, October 2

Continental Breakfast / Networking Roundtables
Ballroom 2
7:00 a.m.-8:00 a.m.

Plenary Session 1: DNA Damage and Repair
Ballroom 1
Session Chairs: Ursula A. Matulonis, Dana-Farber Cancer Institute, Boston, MA, and Roger A. Greenberg, University of Pennsylvania, Philadelphia, PA
8:00 a.m.-10:00 a.m.

8:00 a.m.-8:20 a.m. PARP inhibitors as single agents in combinations for ovarian cancer: What lies ahead?
Ursula A. Matulonis

8:20 a.m.-8:40 a.m. Inhibition of ATR overcomes the PARP inhibitor resistance of BRCA-deficient cancer cells
Lee Zou, MGH Cancer Center/Harvard Medical School, Boston, MA

*Short talk from proffered abstract
8:40 a.m.-9:00 a.m.  Mitotic progression connects DNA damage to activation of anti-tumor immune responses
Roger A. Greenberg

9:00 a.m.-9:10 a.m.  Cyclin E: Targeting cell cycle dependencies in CCNE1 amplified tumors*
Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

9:10 a.m.-9:20 a.m.  Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of
synergy with CHK1 inhibition*
Monicka Wielgos-Bonvallet, NYU Langone Medical Center, New York, NY

9:20 a.m.–10:00 a.m.  Plenary Session 1 Discussion

Break
Grand Ballroom 1
10:00 a.m.-10:30 a.m.

Plenary Session 2: Metabolic Changes in Ovarian Cancer
Ballroom 1
10:30 a.m.-12:30 p.m.

10:30 a.m.-10:50 a.m.  Discovery of IACS-10759, a novel oxidative phosphorylation inhibitor targeting critical
cancer vulnerabilities
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, TX

10:50 a.m.-11:10 a.m.  Stromal regulation of metastasis
Ernst R. Lengyel

11:10 a.m.-11:30 a.m.  Targeting micrometastasis for the treatment of ovarian cancer
Ahmed A. Ahmed

11:30 a.m.-11:50 a.m.  Kinase-mediated modulation of paclitaxel sensitivity in ovarian cancer
Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, TX

11:50 a.m.-12:00 p.m.  Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma*
Jennifer Xiao Ye Ji, University of British Columbia, Vancouver, BC, Canada

12:00 p.m.-12:30 p.m.  Plenary Session 2 Discussion

Free Time (Lunch on Own)
12:30 p.m.-3:00 p.m.

Plenary Session 3: Tumor Microenvironment
Ballroom 1
Session Chairs: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX, and Frances R. Balkwill,
Barts Cancer Institute, London, England
3:00 p.m.-5:00 p.m.

3:00 p.m.-3:20 p.m.  New directions in tumor microenvironment
Anil K. Sood

3:20 p.m.-3:40 p.m.  Deconstructing and reconstructing the ovarian cancer microenvironment
Frances R. Balkwill

3:40 p.m.-4:00 p.m.  Translating preclinical observations into trials addressing changes in the tumor
microenvironment

*Short talk from proffered abstract
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, TX

4:00 p.m.-4:10 p.m.  
Tumor-derived indoleamine 2,3-dioxygenase regulates density of tumor infiltrating CD8+ T cells and myeloid derived suppressor cells in a murine model of ovarian cancer*
Adaobi E. Amobi, Roswell Park Cancer Institute, Buffalo, NY

4:10 p.m.-4:20 p.m.  
Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis*
Mark A. Eckert, University of Chicago, Chicago, IL

4:20 p.m.-5:00 p.m.  
Plenary Session 3 Discussion

Panel Discussion: Innovative Trial Design
Ballroom 1
5:00 p.m.-6:00 p.m.

Panelists:
Elise C. Kohn, CIB/CTEP/DCTD/NCI, Rockville, MD
Michael J. Birrer, UAB Comprehensive Cancer Center, Birmingham, AL

ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs. placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)*
Robert L. Coleman, The University of Texas MD Anderson Cancer Center, Houston, Texas

Poster Session A / Reception
Ballroom 3-4
6:00 p.m.-8:30 p.m.

Tuesday, October 3

Continental Breakfast / Networking Roundtables
Ballroom 2
7:00 a.m.-8:00 a.m.

Plenary Session 4: Drug Response and Resistance to Therapy
Ballroom 1
Session Chair: David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia, and Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas
8:00 a.m.-10:00 a.m.

8:00 a.m.-8:20 a.m.  
Acquired chemotherapy resistance in high-grade serous ovarian cancer patients
David D. L. Bowtell

8:20 a.m.-8:40 a.m.  
Systems approach to drug development
Gordon B. Mills

8:40 a.m.-9:00 a.m.  
Exploiting synthetic lethality in the treatment of gynecological cancers
Christopher Lord, Cancer Research UK London Research Institute, London, United Kingdom

9:00 a.m.-9:10 a.m.  
Combined MEK and BCL-2/XI inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer*
Claudia Iavarone, Ludwig Center at Harvard, Harvard Medical School, Boston, MA

*Short talk from proffered abstract
Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer*  
Anniina Färkkilä, University of Helsinki, Helsinki, Finland

Plenary Session 5: Prevention and Early Detection  
Session Chairs: Robert C. Bast, Jr., The University of Texas MD Anderson Cancer Center, Houston, TX, and Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, MD

9:10 a.m.-9:20 a.m. Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer*  
Anniina Färkkilä, University of Helsinki, Helsinki, Finland

9:20 a.m.-10:00 a.m. Plenary Session 4 Discussion

Break  
Grand Ballroom 1  
10:00 a.m.-10:30 a.m.

10:30 a.m.-10:50 a.m. Early detection of ovarian cancer: An update  
Robert C. Bast, Jr.

10:50 a.m.-11:10 a.m. PapGene, PapSEEK, and PapDREAMing for early detection of ovarian cancer  
Ie-Ming Shih

11:10 a.m.-11:30 a.m. Physical and in silico methods for improving sensitivity of detection of ctDNA for personalized medicine in high grade serous ovarian cancer  
James D. Brenton, University of Cambridge, Cambridge, United Kingdom

11:30 a.m.-11:40 a.m. Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq*  
Kevin M. Elias, Brigham and Women's Hospital, Boston, MA

11:40 a.m.-11:50 a.m. Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study*  
Francesmary Modugno, University of Pittsburgh, Pittsburgh, PA

11:50 a.m.-12:30 p.m. Plenary Session 5 Discussion

Poster Session B / Lunch  
Ballroom 3-4  
12:30 p.m.-3:00 p.m.

Plenary Session 6: Exploiting Vulnerabilities in Rare Tumors  
Session Chairs: David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston, TX, and David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

3:00 p.m.-5:00 p.m.

3:00 p.m.-3:20 p.m. Progress and future directions in the management of low-grade serous cancer of the ovary  
David M. Gershenson

3:20 p.m.-3:40 p.m. Granulosa cell and other rare ovarian cancers: Genomic-derived diagnostics and emergent management strategies  
David G. Huntsman

3:40 p.m.-4:00 p.m. Therapeutic targeting of ARID1A mutation in ovarian cancer  
Rugang Zhang, The Wistar Institute, Philadelphia, PA

4:00 p.m.-4:20 p.m. Small cell carcinomas of the ovary: Strengths and weaknesses  
Douglas A. Levine, New York University, New York, NY

*Short talk from proffered abstract
4:20 p.m.-4:30 p.m.  The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma*  Darren Ennis, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom

4:30 p.m.-5:00 p.m.  Plenary Session 6 Discussion

Panel: Funding Opportunities and Advocacy Groups  
Ballroom 1  
5:00 p.m.-6:00 p.m.

Panelists:  
Kiran Dhillon, Rivkin Center for Ovarian Cancer Research, Seattle, WA  
Annie E. Ellis, Ovarian Cancer Research Fund Alliance, White Plains, NY  
Kathleen Gavin, Minnesota Ovarian Cancer Alliance, Minneapolis, MN  
Kristin Parello-Plesner, OvaCure, Copenhagen, Denmark  
Susan Perkins, National Cancer Institute, Rockville, MD  
Runsi Sen, Ovarcome, Houston, TX  
Katherine Taylor, Ovarian Cancer Action, London, England  
Karen Wylie, Ripple Effect, in support of The Congressionally Directed Medical Research Programs (CDMRP), Frederick, MD

Wednesday, October 4

Continental Breakfast / Networking Roundtables  
King's Garden 5  
7:00 a.m.-8:00 a.m.

Plenary Session 7: Immunotherapy  
Ballroom 1  
Session Chair: Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY, and David R. Spriggs, Memorial Sloan Kettering Cancer Center, New York, NY  
8:00 a.m.-10:00 a.m.

8:00 a.m.-8:20 a.m.  Reprogramming the tumor microenvironment and T cells for ovarian cancer immunotherapy  
Kunle Odunsi

8:20 a.m.-8:40 a.m.  How does the immune system contend with intratumoral heterogeneity in ovarian cancer?  
Brad Nelson, BC Cancer Agency, Vancouver Island, BC, Canada

8:40 a.m.-9:00 a.m.  Translating fundamental immunobiology into adoptive T cell therapy for ovarian cancer  
Daniel J. Powell, University of Pennsylvania, Philadelphia, PA

9:00 a.m.-9:20 a.m.  Strategies for glycosylation-based immunotargeting of MUC16  
David R. Spriggs

9:20 a.m.-9:30 a.m.  Epigenetic reprogramming promotes an immunogenic ovarian tumor microenvironment and synergizes with adoptive transfer of engineered T cells expressing NY-ESO-1 specific T cell receptors*  
Li Shen, Roswell Park Cancer Institute, Buffalo, NY

9:30 a.m.-10:00 a.m.  Plenary Session 7 Discussion

*Short talk from proffered abstract
Break
Grand Ballroom 1
10:00 a.m.-10:15 a.m.

Plenary Session 8: Genetics and Molecular Drivers
Ballroom 1
Session Chairs: Ronny I. Drapkin, University of Pennsylvania, Philadelphia, PA, and Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada
10:15 a.m.-12:15 p.m.

10:15 a.m.-10:35 a.m.  Replication road blocks in Cyclin E-amplified ovarian cancers
Ronny I. Drapkin

10:35 a.m.-10:55 a.m.  Functional genetic architecture of serous ovarian cancer
Robert K. Rottapel

10:55 a.m.-11:15 a.m.  Title to be announced
Andy Futreal, The University of Texas MD Anderson Cancer Center, Houston, TX

11:15 a.m.-11:25 a.m.  TERT is frequently mutated in adult-type granulosa cell tumors of the ovary compared to other malignant sex cord-stromal tumors*
Jessica A. Pilsworth, University of British Columbia, Vancouver, BC, Canada

11:25 a.m.-11:45 a.m.  CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high grade serous carcinoma*
Josephine Walton, The University of Glasgow, Glasgow, United Kingdom

11:45 a.m.-12:15 p.m.  Plenary Session 8 Discussion

Departure
12:15 p.m.

*Short talk from proffered abstract